NO954342D0 - Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav - Google Patents

Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav

Info

Publication number
NO954342D0
NO954342D0 NO954342A NO954342A NO954342D0 NO 954342 D0 NO954342 D0 NO 954342D0 NO 954342 A NO954342 A NO 954342A NO 954342 A NO954342 A NO 954342A NO 954342 D0 NO954342 D0 NO 954342D0
Authority
NO
Norway
Prior art keywords
processes
preparation
well
erythropoietin analog
analog mixtures
Prior art date
Application number
NO954342A
Other languages
English (en)
Other versions
NO954342L (no
Inventor
Gregory F Okasinski
Peter J Devries
Barry S Mellovitz
Joseph L Meuth
Verlyn G Schaefer
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NO954342L publication Critical patent/NO954342L/no
Publication of NO954342D0 publication Critical patent/NO954342D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO954342A 1993-04-29 1995-10-30 Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav NO954342D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5507693A 1993-04-29 1993-04-29
PCT/US1994/004755 WO1994025055A1 (en) 1993-04-29 1994-04-29 Erythropoietin analog compositions and methods

Publications (2)

Publication Number Publication Date
NO954342L NO954342L (no) 1995-10-30
NO954342D0 true NO954342D0 (no) 1995-10-30

Family

ID=21995426

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954342A NO954342D0 (no) 1993-04-29 1995-10-30 Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav

Country Status (13)

Country Link
US (1) US5888772A (no)
EP (1) EP0744953A4 (no)
JP (1) JPH08509614A (no)
KR (1) KR960701650A (no)
CN (1) CN1125401A (no)
AU (1) AU697453B2 (no)
BR (1) BR9406490A (no)
CA (1) CA2161651A1 (no)
CZ (1) CZ286046B6 (no)
FI (1) FI955128A0 (no)
HU (1) HUT73876A (no)
NO (1) NO954342D0 (no)
WO (1) WO1994025055A1 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
KR100400637B1 (ko) * 1996-02-06 2004-03-10 씨제이 주식회사 생물학적으로유용한펩타이드
US5835382A (en) * 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
EP1731174A3 (en) 1996-08-02 2007-01-17 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
MXPA00010070A (es) * 1998-04-15 2004-03-10 Lexigen Pharm Corp Mejora de respuestas inmunes medidas de proteina de fusion anticuerpo-citoquina por co-administracion con inhibidor de angiogenesis.
EP1088084B1 (en) 1998-06-15 2006-09-13 GTC Biotherapeutics, Inc. Erythropoietin analog-human serum albumin fusion protein
EP1135493A2 (en) * 1998-11-30 2001-09-26 Eli Lilly And Company Erythropoietic compounds
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU778611B2 (en) * 1999-08-09 2004-12-16 Merck Patent Gmbh Multiple cytokine-antibody complexes
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2391080A1 (en) * 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
RU2272644C2 (ru) * 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
KR20030046411A (ko) * 2000-09-08 2003-06-12 그리폰 테라퓨틱스, 인코포레이티드 '위'-천연 화학적 라이게이션
WO2002024899A2 (en) 2000-09-25 2002-03-28 Valentis, Inc. Improved system for regulation of transgene expression
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
PL206701B1 (pl) * 2001-03-07 2010-09-30 Merck Patent Gmbh Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
DE60239454D1 (de) * 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
BR0214650A (pt) * 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
NZ537306A (en) * 2002-07-01 2008-11-28 Kenneth S Warren Inst Inc Compositions comprising mutein recombinant tissue protective cytokines having one or more amino acid substitutions facilitating transport of a molecule via transcytosis across an endothelial cell barrier
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
MXPA05006384A (es) * 2002-12-17 2005-08-29 Merck Patent Gmbh Anticuerpo humanizado (h14.18) del anticuerpo 14.18 de raton enlazado a gd2 y su fusion con il-2.
EP1608672A4 (en) * 2003-04-02 2007-11-21 Epimmune Inc PEPTIDES, POLYPEPTIDES AND PROTEINS OF REDUCED IMMUNOGENICITY AND METHODS OF PRODUCTION THEREOF
EP1615945B1 (en) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylation methods and proteins/peptides produced by the methods
US7459152B2 (en) * 2003-04-23 2008-12-02 Rush University Medical Center Erythropoietin administration to improve graft survival
US7645733B2 (en) * 2003-09-29 2010-01-12 The Kenneth S. Warren Institute, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
BRPI0417916A (pt) * 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
DE102004063927A1 (de) 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
WO2009100255A2 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
WO2007136752A2 (en) 2006-05-19 2007-11-29 Glycofi, Inc. Erythropoietin compositions
KR101248252B1 (ko) 2006-11-28 2013-03-27 한올바이오파마주식회사 변형된 에리스로포이에틴 폴리펩티드와 이의 치료용 용도
CN103113464B (zh) * 2007-07-02 2014-08-20 沈阳三生制药有限责任公司 天然人促红细胞生成素类似物
US20100298219A1 (en) * 2008-01-22 2010-11-25 Anthony Cerami Method of treating cancer, neoplastic disorders, and symptoms thereof with compounds
PE20110832A1 (es) 2008-09-26 2011-11-24 Ambrx Inc Polipeptidos de eritropoyetina felina modificados
US20100272816A1 (en) 2009-04-27 2010-10-28 Wolfgang Rudinger Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
US20130034875A1 (en) * 2009-10-01 2013-02-07 Toto Ltd. Dna construct, and process for production of recombinant cho cell using same
CN102205114B (zh) * 2011-04-29 2012-12-12 中国人民解放军第三军医大学 促红细胞生成素来源肽在制备治疗神经系统自身免疫性疾病的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
DE3923963A1 (de) * 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung

Also Published As

Publication number Publication date
CZ284495A3 (en) 1996-02-14
EP0744953A4 (en) 1998-05-06
KR960701650A (ko) 1996-03-28
FI955128A (fi) 1995-10-27
BR9406490A (pt) 1996-03-05
CN1125401A (zh) 1996-06-26
JPH08509614A (ja) 1996-10-15
AU6778594A (en) 1994-11-21
HU9503088D0 (en) 1995-12-28
AU697453B2 (en) 1998-10-08
NO954342L (no) 1995-10-30
WO1994025055A1 (en) 1994-11-10
CA2161651A1 (en) 1994-11-10
US5888772A (en) 1999-03-30
HUT73876A (en) 1996-10-28
CZ286046B6 (cs) 1999-12-15
FI955128A0 (fi) 1995-10-27
EP0744953A1 (en) 1996-12-04

Similar Documents

Publication Publication Date Title
NO954342D0 (no) Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav
NO941104D0 (no) Asfaltblandinger, samt fremgangsmåte ved fremstilling derav
DE4494905T1 (de) Spektrometer
ES1026992Y (es) Barandilla, manija o analogo.
FR2709812B1 (fr) Procédé de combustion.
BR9400604A (pt) Processo para a preparação de 1,1,1,3,3-pentafluorpropano
FI943553A0 (fi) Upokas, erityisesti tukiupokas
NO900648D0 (no) Seksjonsdelt strekkramme for malerlerret.
GB2287953B (en) High stability, organic tanning processes
BR9407024A (pt) Processo para a preparação de 4,6-diamino-5-cianopirimidinas substituídas
NO902334D0 (no) Fremgangsmaate ved fremstilling av beholdere.
FI901546A0 (fi) Kompositioner innehaollande 2-tiocyanometyltiobensotiazol foer anvaendning i industriella mikrobiocider.
BR9007862A (pt) Tinturas de benzoxazina
NO931865D0 (no) Anordning ved kjernebor
NO880100L (no) Fremgangsmaate ved utskiftning av anoder.
DE69002476D1 (de) Kationisches elektro-abscheidbares anstrichmittel.
NO950223D0 (no) Fremgangsmåte for fremstilling av kjeks, samt slik kjeks
ES1025981Y (es) Director-extractor de gases.
FR2706142B1 (fr) Rasoir de sûreté.
BR9305542A (pt) Processo para a preparação de 5-alcóxi-2,4-dinitro-alquilbenzenos
AU7695094A (en) Alkyl-1-alkyl-4-hydroxy-2-oxo-1,8-naphthyridine-3-carboxylat es as anti-rheumatic agents
DE68902045T2 (de) Aerosollack.
NO931435D0 (no) Anordning ved leddport
KR950013225U (ko) 약탕 증류기
NO943422L (no) Anordninger ved forskalingskassetter, samt slike forskalingskassetter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application